Veradigm Provides Business and Strategy Update
“On my first investor call in October, I committed to advancing three strategic objectives in my first 100 days: reset our business strategy, recover our market leadership with independent physician practices and reignite profitable growth,” said
“We closed fiscal 2025 in line with our expectations. Our topline performance held steady. Our capital position remained strong,” said
Management currently estimates the following preliminary unaudited financials:
-
Revenue on a GAAP basis in a range between
$590 million and$595 million for fiscal year endingDecember 31, 2024 , revised upward from the prior outlook issued onMarch 18, 2025 . -
Revenue on a GAAP basis in a range between
$584 million and$589 million for fiscal year endingDecember 31, 2025 , down 1% at the mid-point of ranges compared to full year 2024. -
Cash and equivalents of
$120 million as ofDecember 31, 2025 as compared to$294 million as ofDecember 31, 2024 .-
Cash and equivalents decreased by
$174 million . The change in cash was driven by:-
$159 million of net outflows from debt financing activities, which included repurchasing our Convertible Notes and issuing new senior secured debt(1) -
$14 million of outflows for prior acquisitions -
$31 million of net inflows from investment portfolio activity -
$62 million of outflows for Transaction and other expenses(2) -
$62 million of net inflows from operational items that include working capital, interest, taxes and other -
$32 million of outflows for capital expenditures
-
-
Cash and equivalents decreased by
-
Debt of approximately
$75 million as ofDecember 31, 2025 , consisted of the senior secured term loan credit facility (the “Term Loan Facility”) with a maturity date ofJune 18, 2030 .
As of
|
(1) |
Net outflows from debt financing activities of |
|
(2) |
Transaction and other revenue and expenses relate to certain favorable and unfavorable legal settlements, severance, investigations, internal reviews, restatement-related accounting advisory services and legal services and other charges incurred in connection with activities that are considered not reflective of our core business. |
Investor Conference Call and Webcast
As previously disclosed, Veradigm management plans to host an investor conference call and webcast to discuss the Company’s update at
To listen to the conference call, participants may log onto the Veradigm investor relations website. Participants also may access the conference call by dialing 877-405-1224 or 201-389-0848 and requesting Access ID # 13758731.
A replay of the call will be available for a period of one year on the Veradigm investor relations website.
About Veradigm®
Veradigm has a proven history of delivering clinical and revenue cycle solutions that help independent practices improve outcomes and financial performance. Our AI-forward data and technology also help over 20,000 provider practices connect with health plans and biopharma to eliminate inefficiencies, close care gaps, and create a more affordable health system.
© 2026
Disclaimer and Forward-Looking Statement Information
The estimated financial results contained in this press release are preliminary results, and the final results for the 2024 and 2025 fiscal years may change. These preliminary results are based upon the Company’s estimates and are subject to completion of the Company’s financial closing procedures. In addition, these preliminary results have not been audited by the Company’s independent registered public accounting firm.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, the Company’s strategic initiatives under its new leadership. These forward-looking statements are based on the current beliefs and expectations of the Company’s management with respect to future events, only speak as of the date that they are made, and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “continue,” “can,” “may,” “look forward,” “aims,” “hopes,” and “seeks” and similar terms, although not all forward-looking statements contain such words or expressions. Actual results could differ significantly from those set forth in the forward-looking statements.
Important factors that may cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, risks relating to the Company’s common stock not trading on a national securities exchange and deregistration from Section 12(b) of the Securities Exchange Act of 1934, as amended; a further material delay in the Company’s financial reporting or ability to hold an annual meeting of stockholders; an inability of the Company to timely prepare its delinquent financial statements; unanticipated factors or factors that the Company currently believes will not cause further delay; the Company’s remediation efforts and preparation of financial statements or other factors that could cause additional delay or adjustments; the possibility that ongoing remediation work or the audit of the Company’s financial statements for the fiscal years ended
|
Table 1 |
|||
|
|
|||
|
Revenue |
|||
|
(Issued |
|||
|
(In millions) |
|||
|
(Unaudited) |
|||
|
Twelve Months Ended |
|||
|
2025 |
2024 |
||
| Provider1 | |||
| Revenue, GAAP2 |
|
|
|
| Payer & Life Science1 | |||
| Revenue, GAAP |
|
|
|
| Total Veradigm | |||
| Revenue, GAAP2 |
|
|
|
| 1 Supplemental financial information | |||
| 2 Estimated revenue includes favorable customer settlement of approximately, |
|||
|
Table 2 |
||||
|
|
||||
|
Cash and Debt |
||||
|
(Issued |
||||
|
(In millions) |
||||
|
(Unaudited) |
||||
|
|
|
|||
|
2025 |
2024 |
|||
| Cash and cash equivalents, end of period |
|
|
||
| Debt1 |
|
|
||
| 1 Consisting of the principal amount of the 2019 convertible notes in 2024 and the senior secured term loan credit facility in 2025 | ||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20260217785258/en/
Veradigm Contacts:
Investors:
312-506-1237
jenny.gelinas@veradigm.com
Media:
732-567-7607
amanda.cohen@veradigm.com
Source: Veradigm